Trial
NCT02539459
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
Novartis Pharmaceuticals
Condition
Sporadic Angiomyolipomas (AMLs)
Intervention
Everolimus
Why stopped
Extreme toxicity, met toxicity stopping rules
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-15